Literature DB >> 27080977

A Nationally Representative Study of Calcific Uremic Arteriolopathy Risk Factors.

Sagar U Nigwekar1, Sophia Zhao2, Julia Wenger3, Jeffrey L Hymes4, Franklin W Maddux4, Ravi I Thadhani2, Kevin E Chan2,4.   

Abstract

Accurate identification of risk factors for calcific uremic arteriolopathy (CUA) is necessary to develop preventive strategies for this morbid disease. We investigated whether baseline factors recorded at hemodialysis initiation would identify patients at risk for future CUA in a matched case-control study using data from a large dialysis organization. Hemodialysis patients with newly diagnosed CUA (n=1030) between January 1, 2010, and December 31, 2014, were matched by age, sex, and race in a 1:2 ratio to hemodialysis patients without CUA (n=2060). Mean ages for patients and controls were 54 and 55 years, respectively; 67% of participants were women and 49% were white. Median duration between hemodialysis initiation and subsequent CUA development was 925 days (interquartile range, 273-2185 days). In multivariable conditional logistic regression analyses, diabetes mellitus; higher body mass index; higher levels of serum calcium, phosphorous, and parathyroid hormone; and nutritional vitamin D, cinacalcet, and warfarin treatments were associated with increased odds of subsequent CUA development. Compared with patients with diabetes receiving no insulin injections, those receiving insulin injections had a dose-response increase in the odds of CUA involving lower abdomen and/or upper thigh areas (odds ratio, 1.49; 95% confidence interval, 1.03 to 2.51 for one or two injections per day; odds ratio, 1.88; 95% confidence interval, 1.30 to 3.43 for 3 injections per day; odds ratio, 3.74; 95% confidence interval, 2.28 to 6.25 for more than three injections per day), suggesting a dose-effect relationship between recurrent skin trauma and CUA risk. The presence of risk factors months to years before CUA development observed in this study will direct the design of preventive strategies and inform CUA pathobiology.
Copyright © 2016 by the American Society of Nephrology.

Entities:  

Keywords:  clinical epidemiology; diabetes mellitus; end stage kidney disease; hemodialysis; obesity; vascular calcification

Mesh:

Year:  2016        PMID: 27080977      PMCID: PMC5084892          DOI: 10.1681/ASN.2015091065

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  31 in total

1.  Calciphylaxis: natural history, risk factor analysis, and outcome.

Authors:  Roger H Weenig; Lindsay D Sewell; Mark D P Davis; James T McCarthy; Mark R Pittelkow
Journal:  J Am Acad Dermatol       Date:  2006-12-01       Impact factor: 11.527

Review 2.  Observational studies versus randomized controlled trials: avenues to causal inference in nephrology.

Authors:  Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  Adv Chronic Kidney Dis       Date:  2012-01       Impact factor: 3.620

3.  Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis.

Authors:  Glenn M Chertow; Geoffrey A Block; Ricardo Correa-Rotter; Tilman B Drüeke; Jürgen Floege; William G Goodman; Charles A Herzog; Yumi Kubo; Gerard M London; Kenneth W Mahaffey; T Christian H Mix; Sharon M Moe; Marie-Louise Trotman; David C Wheeler; Patrick S Parfrey
Journal:  N Engl J Med       Date:  2012-11-03       Impact factor: 91.245

4.  Statin use and calcific uremic arteriolopathy: a matched case-control study.

Authors:  Sagar U Nigwekar; Ishir Bhan; Alexander Turchin; Stephen C Skentzos; Reza Hajhosseiny; David Steele; Rosalynn M Nazarian; Julia Wenger; Samir Parikh; Ananth Karumanchi; Ravi Thadhani
Journal:  Am J Nephrol       Date:  2013-03-21       Impact factor: 3.754

5.  Heritability of Risk for Sudden Cardiac Arrest in ESRD.

Authors:  Kevin E Chan; Christopher Newton-Cheh; James F Gusella; Franklin W Maddux
Journal:  J Am Soc Nephrol       Date:  2015-04-16       Impact factor: 10.121

6.  The Effect of Cinacalcet on Calcific Uremic Arteriolopathy Events in Patients Receiving Hemodialysis: The EVOLVE Trial.

Authors:  Jürgen Floege; Yumi Kubo; Anna Floege; Glenn M Chertow; Patrick S Parfrey
Journal:  Clin J Am Soc Nephrol       Date:  2015-04-17       Impact factor: 8.237

7.  Calciphylaxis is usually non-ulcerating: risk factors, outcome and therapy.

Authors:  Adrian Fine; James Zacharias
Journal:  Kidney Int       Date:  2002-06       Impact factor: 10.612

8.  Calciphylaxis in patients on hemodialysis: a prevalence study.

Authors:  M Angelis; L L Wong; S A Myers; L M Wong
Journal:  Surgery       Date:  1997-12       Impact factor: 3.982

9.  Sodium thiosulfate therapy for calcific uremic arteriolopathy.

Authors:  Sagar U Nigwekar; Steven M Brunelli; Debra Meade; Weiling Wang; Jeffrey Hymes; Eduardo Lacson
Journal:  Clin J Am Soc Nephrol       Date:  2013-03-21       Impact factor: 8.237

10.  Adipocyte induced arterial calcification is prevented with sodium thiosulfate.

Authors:  Neal X Chen; Kalisha O'Neill; Nader Kassis Akl; Sharon M Moe
Journal:  Biochem Biophys Res Commun       Date:  2014-05-10       Impact factor: 3.575

View more
  47 in total

1.  Vitamin K-Dependent Carboxylation of Matrix Gla Protein Influences the Risk of Calciphylaxis.

Authors:  Sagar U Nigwekar; Donald B Bloch; Rosalynn M Nazarian; Cees Vermeer; Sarah L Booth; Dihua Xu; Ravi I Thadhani; Rajeev Malhotra
Journal:  J Am Soc Nephrol       Date:  2017-01-03       Impact factor: 10.121

2.  K-alcification Protection in Dialysis Patients: The Underestimated Phenomenon of Vitamin K Deficiency.

Authors:  Markus Ketteler; Vincent Matthias Brandenburg
Journal:  J Am Soc Nephrol       Date:  2017-04-03       Impact factor: 10.121

3.  Localization, Morphologic Features, and Chemical Composition of Calciphylaxis-Related Skin Deposits in Patients With Calcific Uremic Arteriolopathy.

Authors:  Hester Colboc; Philippe Moguelet; Dominique Bazin; Priscille Carvalho; Anne-Sophie Dillies; Guillaume Chaby; Hervé Maillard; Diane Kottler; Elisa Goujon; Christine Jurus; Marine Panaye; Vincent Frochot; Emmanuel Letavernier; Michel Daudon; Ivan Lucas; Raphaël Weil; Philippe Courville; Jean-Benoit Monfort; François Chasset; Patricia Senet
Journal:  JAMA Dermatol       Date:  2019-07-01       Impact factor: 10.282

4.  Calcific Uremic Arteriolopathy Revisited.

Authors:  Anna Jovanovich; Michel Chonchol
Journal:  J Am Soc Nephrol       Date:  2016-05-25       Impact factor: 10.121

5.  Multidisciplinary management of calciphylaxis: a series of 5 patients at a single facility.

Authors:  Tomohiro Saito; Yuuki Mima; Motonori Sugiyama; Nozomi Miyazawa; Ayana Iida; Nobuhiro Kanazawa; Taihei Suzuki; Yasuto Shikida; Toma Hamada; Yukihiro Wada; Masahide Mizobuchi; Hirokazu Honda
Journal:  CEN Case Rep       Date:  2019-12-17

6.  Increased Bone Morphogenetic Protein Signaling in the Cutaneous Vasculature of Patients with Calciphylaxis.

Authors:  Sagar U Nigwekar; Pawina Jiramongkolchai; Florian Wunderer; Emily Bloch; Rika Ichinose; Rosalynn M Nazarian; Ravi I Thadhani; Rajeev Malhotra; Donald B Bloch
Journal:  Am J Nephrol       Date:  2017-11-09       Impact factor: 3.754

Review 7.  Calciphylaxis.

Authors:  Sagar U Nigwekar
Journal:  Curr Opin Nephrol Hypertens       Date:  2017-07       Impact factor: 2.894

8.  Effectiveness and Safety of Direct Oral Anticoagulants in an Asian Population with Atrial Fibrillation Undergoing Dialysis: A Population-Based Cohort Study and Meta-Analysis.

Authors:  Lai-Chu See; Hsin-Fu Lee; Tze-Fan Chao; Pei-Ru Li; Jia-Rou Liu; Lung-Sheng Wu; Shang-Hung Chang; Yung-Hsin Yeh; Chi-Tai Kuo; Yi-Hsin Chan; Gregory Y H Lip
Journal:  Cardiovasc Drugs Ther       Date:  2020-11-19       Impact factor: 3.727

9.  Clinical characteristics and risk factors associated with mortality in calcific uremic arteriolopathy.

Authors:  Peter W Santos; Jianghua He; Ahmad Tuffaha; James B Wetmore
Journal:  Int Urol Nephrol       Date:  2017-10-20       Impact factor: 2.370

10.  Non-uraemic calciphylaxis (NUC) postliver transplantation.

Authors:  Simona Frunza-Stefan; Silpa Poola-Kella; Kristi Silver
Journal:  BMJ Case Rep       Date:  2018-10-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.